A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of DII235 in Adults With Elevated Lipoprotein(a)
Latest Information Update: 01 Jan 2026
At a glance
- Drugs DII 235 (Primary)
- Indications Hyperlipoproteinaemia
- Focus Therapeutic Use
- Sponsors Novartis
Most Recent Events
- 12 Dec 2025 Status changed from not yet recruiting to recruiting.
- 02 Dec 2025 New trial record